Datum | Källa | Rubrik | Typ | Alternativ | ||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-05-03 | Penser Access by Carnegie | Penser Access by Carnegie: Interview with Mentice - Carnegie Investment Bank - May 3rd, 2024 | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-05-03 | Mentice | Mentice publishes the company’s interim report for the period January – March 2024 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-05-03 | Mentice | Mentice publicerar bolagets delårsrapport för perioden januari–mars 2024 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-04-26 | Mentice | Mentice to present the company's Q1 Interim Report | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-04-24 | Mentice | Correction: Mentice publishes Annual Report 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-04-24 | Mentice | Rättelse: Mentice publicerar årsredovisning 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-04-24 | Mentice | Mentice publicerar årsredovisning 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-04-24 | Mentice | Mentice publishes Annual Report 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-04-23 | Mentice | Kallelse till årsstämma i Mentice AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-04-23 | Mentice | Annual shareholders’ meeting in Mentice AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
Pressreleaser |
Annual shareholders’ meeting in Mentice ABThe shareholders in Mentice AB, reg. no. 566556-4241, (the “Company”), are hereby invited to attend the annual shareholders’ meeting to be held on 23 May 2024 at 10.00 a.m at Scandic Crown, Polhemsplatsen 3, 411 11 Gothenburg. Right to participate and notice Notice of intent to participate in the annual shareholders’ meeting can be given in writing to Mentice AB, att: Mentice AB, Annual Shareholders’ Meeting, Odinsgatan 10, 411 03 Gothenburg, or by e-mail to stefani.erceg@mentice.com. The notice ought to specify the shareholder’s name, personal identity or company registration number, address, work-hour telephone number and shareholding, and names of any advisors. Trustee-registered shares Proxies In order to facilitate registration, power of attorney and documents of authorization should be the Company to hand at the abovementioned address on 17 May 2024 at the latest. Proposed agenda
Resolution proposals Item 8 (b): The board of directors proposes that the year’s loss be disposed of in accordance with the disposal proposal included in the management report and that no dividend be distributed. Item 8 (c): The auditor endorses that the annual general meeting discharges the members of the board of directors and the managing director from liability for the financial year of 2023. Resolutions regarding discharge from liability are made through individual, and separate decision for each of the board members and the managing director in the following order:
Item 9 : In accordance with the nomination committee’s proposal, it is proposed that the annual shareholders’ meeting shall resolve to determine that a fixed yearly fee of in total SEK 1,270,000 whereof SEK 110,000 shall be paid to Johann Koss, SEK 190,000 shall be paid to Gösta Johannesson, Eola Änggård Runsten, David Ballard and Denis Gestin respectively and SEK 400,000 shall be paid to Magnus Nilsson. Lawrence D Howell refrains from being renumerated. The payment is subject to the condition that the board member is elected by the annual shareholders’ meeting and is not employed by the Company or any of its subsidiaries. The nomination committee furthermore proposes that the fee for the audit committee shall be determined to SEK 60,000 for the chairman and SEK 30,000 per other member. In addition to this, the nomination committee proposes fees to the remuneration committee to SEK 40,000 for the chairman and SEK 20,000 per other member. Fees to the Company’s auditor is proposed to be paid according to approved invoice. Item 10: In accordance with the nomination committee’s proposal, it is proposed that the Company’s board of directors should consist of seven board members without deputies. It is proposed for the time being until the end of the next annual shareholders’ meeting that the Company should have a registered auditing firm without change as an auditor alternate. Furthermore, it is proposed that as ordinary members of the board of directors shall, until the next annual shareholders’ meeting, be elected Lawrence D. Howell, Denis Gestin, Gösta Johannesson, David Ballard, Eola Änggård Runsten, Johann Koss and Magnus Nilsson (all re-elected). A presentation of the persons that the nomination committee have proposed as board of directors are available at the Company’s website, www.mentice.com . In accordance with the nomination committee’s proposal, it is proposed that Magnus Nilsson shall be appointed chairman of the board (re-election) and that KPMG AB (re-election) with Johan Kratz (re-election) as principal auditor is appointed as the Company’s auditor without deputy auditors. Item 11 : The board of directors of Mentice AB proposes that the annual shareholders’ meeting resolves on the adoption of guidelines for remuneration and other employment conditions for the senior management. The guidelines also apply to board members in so far as they receive remuneration for services provided to the company or any subsidiaries outside of the scope of the board assignment. Scope: These guidelines shall encompass those persons that are members of the senior management of the company during the period when the guidelines are in force. The guidelines are applicable on agreements entered into after the resolution of the annual shareholders’ meeting, and as far as changes are made to existing agreements, thereafter. The guidelines do not include remuneration resolved by the shareholders’ meeting, such as remuneration for board members or share-based incentive programs. More information regarding Mentice vision and business plan can be found in Mentice financial reports at https://www.mentice.com/financial-reports-presentations . In order for Mentice to be able to execute the company’s business strategy and care for the company’s long-term interests, including sustainability, it is necessary that Mentice can recruit and retain qualified employees. In order to achieve this, Mentice is required to be able to offer competitive remuneration solutions, which these guidelines facilitate. Remuneration: The main principle is that remuneration and other employment conditions for members of the senior management shall be based on market terms and be competitive in order to ensure that the company can attract and retain competent members of the senior management at a reasonable cost for the company. The total remuneration for the senior management shall consist of fixed salary, variable remuneration, pension and other benefits. In order to avoid that the senior management is encouraged to take unreasonable risks, there shall be a fundamental balance between fixed and variable remuneration. The fixed salary shall thus be large enough in relation to the total remuneration paid to the member of the senior management in order to render it possible to reduce the variable remuneration to zero. The variable remuneration to a member of the senior management whose function or total remuneration level implies that he or she can have a material effect on the company’s risk profile, may not be greater than 5 times the yearly fixed salary. Regarding employments that are regulated by laws and regulations other than Swedish, necessary adjustments may be adopted regarding pension benefits and other benefits in order to follow such imperative regulations or fixed local customs, whereas these guidelines’ overall purpose shall be applied as far as possible. Fixed salary: Each member of the senior management shall be offered a fixed salary on market terms, based on the work instructions, degree of difficulty of the work performed, as well as experience, responsibilities, competence and performance. The fixed salary shall be adjusted annually. Variable remuneration: In addition to the fixed annual salary, the members of the company senior management may be offered variable remuneration which shall be paid in cash and based on the result in relation to performance goals within the respective area of responsibility and be in line with the shareholders’ interests. Variable remuneration shall correspond to a maximum of 50% of the fixed annual salary for the CEO and a maximum of 50% of the fixed annual salary for other members of the company senior management, without members of the senior management within sales management, meaning employee whose primary function is sales. Should variable remuneration paid have been based on information that later shows to have been evidently incorrect, the company shall have the possibility to request repayment. Variable remuneration shall be based on clear, predetermined and measurable criteria and financial results and predefined individual and operational goals, as well as designed with the objective to promote the company’s business plan, long-term value creation, including sustainability. The board of directors shall determine the criteria’s yearly. The variable remuneration is to have a cap. The maximum cap for total variable remuneration to the senior management shall be set annually in connection with the establishment of goals for the coming financial year. Additional variable remuneration can be provided due to extraordinary circumstances, provided that such extraordinary arrangements are solely made on an individual level in order to either recruit or retain members of the senior management, or as remuneration for an extraordinary work performance beyond the persons ordinary work tasks. Such remuneration may not supersede a sum corresponding to 50 percent of the annually fixed salary and may not be provided more than once a year per person. Resolutions regarding such remuneration shall be made by the board of directors. Pension: Members of the senior management shall, unless otherwise specifically agreed upon, be offered pension terms which are in accordance with the market in the country where the members of the senior management are habitually resident. Variable remuneration shall, as a main rule, not be pension qualifying. Other benefits: Other benefits such as a company car, additional health insurance and medical benefits shall be limited in value in relation to other remuneration, and shall be paid only in so far as it is considered to be in accordance with the market for other members of senior managements holding corresponding positions on the employment market where the member in question is operating. Long-term share based incentive programmes: The annual shareholders’ meeting 2023 resolved to implement an incentive program available for employees in the company’s group and certain consultants tied to the group. Senior executives may also be offered the opportunity to participate in long-term incentive program, which the board of directors proposes at the annual shareholders meeting. Under such incentive programs, senior executives will have the opportunity to subscribe and be allotted warrants against payment in cash corresponding to the warrants market value. Each warrant would entitle the holder to subscribe for one new share in the company against cash payment at a determined subscription price. Since the price per each warrant would correspond to the market value, the company’s assessment is that no payroll expenses or social security contributions will occur for the company in relation to such incentive program. The board of directors shall each year consider whether the annual shareholders’ meeting is to be proposed to adopt a share-based incentive program. Proposed incentive programs shall contribute to a long-term value growth. It shall be possible to offer members of the senior management corresponding incentives as should have been offered pursuant to a share-based incentive program, should it show to be practically impossible to effectuate such program in the tax domicile of a member of the senior management, or if the company assesses that such participation cannot take place at reasonable administrative costs or financial contributions. The cost and the investment for the company as well as the incentive and financial outcome for the senior management member in question shall under those circumstances essentially correspond to the share-based incentive program. Notice: The notice period upon notice given by the company shall be no longer than 12 months for members of the senior management, with a right to redundancy payment after the expiration of the notice period corresponding to not more than 100% of the fixed salary for a maximum of 12 months, meaning that the fixed salary and redundancy payment shall together not exceed 24 months’ fixed salary. Any right to redundancy payment shall, as a main rule, decrease in situations where remuneration is received from another employer. Upon notice given by a member of the senior management, the notice period shall generally be 6 months for the CEO and 3-6 months for other members of the senior management. Remuneration to board members: If a board member that is elected by the shareholders’ meeting is performing work for Mentice that stretches beyond the tasks of the board of directors, it shall be possible to pay such member of the board of directors for such work through consulting fees to the board member or to a by the board member controlled company provided that the performed work contributes to the implementation of Mentice business strategy as well as the procurement of the long-term interest of Mentice, including its sustainability. Such remuneration shall be market based and shall be approved by the board of directors. Salary and terms of employment for employees: When preparing of the board of directors proposal for these remuneration guidelines, factors such as salary and terms of employment for the company’s employees have been taken into account through the review of information regarding the employees total remuneration, the remuneration components as well as the remuneration increase and pace of increase over time, which have all constituted part of the board of directors’ basis for decision when evaluating the reasonability and the limitations of the guidelines. Deviations from the guidelines: The board of directors shall be entitled to deviate from the guidelines in individual cases if there are special reasons for doing so and if it is necessary in order to facilitate the long-term interests of the company, including sustainability. During 2023 no deviations from the adopted guidelines have been applied. Significant changes to the guidelines: The proposal for guidelines presented at the shareholders’ Meeting 2024 does not entail any significant changes in relation to the company’s existing remuneration guidelines. Item 12 : The board of directors in Mentice AB proposes that the annual shareholders’ meeting resolves to authorise the board of directors, until the next annual shareholders’ meeting, on one or several occasions, with or without deviation from the shareholders’ preferential rights, to resolve on new issues of shares and/or issues of warrants, entitling the holders to subscribe for new shares and/or issues of convertibles, entitling the holders to convert the convertibles to new shares. Issues may be undertaken against cash payment and/or with provisions regarding issue in kind or set off or other provision. The maximum number of shares to be issued under this authorisation together with any shares possibly issued in connection with use of options and converting of convertibles shall not exceed 2,556,885 shares, implying a maximum dilution of equity of approximately 10 per cent of all outstanding shares in Mentice AB at the time of this resolution proposal. The incentive for this proposal and the reasons for deviation from the shareholders’ preferential rights and/or the possibility to resolve on issuing of new shares with provisions on issue in kind, set off or other provisions, is to provide the board of directors with flexibility within the Company financing and to enable an accelerated expansion and development of the Company, its markets and products by e.g. acquisition of enterprises, businesses or other assets where payment wholly or partially shall be made with new issued shares and/or the enable the board of directors to swiftly obtain funds for such acquisitions. The Board of Directors or the person appointed by the board of directors is authorised, to make such minor formal adjustments to the resolution, which may be required for registration with the Swedish Companies Registration Office and Euroclear Sweden AB. For a valid resolution, this proposal has to be supported by shareholders with at least two thirds of the votes cast as well as of the shares represented at the meeting. Item 13 (A)-(B) : The Board of Directors’ of Mentice AB (the “ Company ” or “ Mentice ”) propose that the Annual General Meeting resolve on (13 A.) the adoption of an incentive programme in the form of performance-based share option rights directed at the group management and key individuals of the Mentice group (the “ SORP 2024 ”). The resolution pursuant to item (13 A.) shall also be conditional on the Annual General Meeting resolving on a directed issue of warrants in accordance with the Board’s proposal under item (13 B.) below. 13 A. Introduction of the SORP 2024 Background and rationale Summary of the programme Under the SORP 2024, participants are given the opportunity to receive shares free of charge, so called “ Performance Shares ”, in accordance with the terms and conditions described below. An offer to participate in the SORP 2024 shall be made as soon as practicably possible. Within the scope of the SORP 2024, the Board of Directors will grant participants rights free of charge entailing the right to, provided that certain criteria are fulfilled, receive Performance Shares (“ Rights ”). Terms and conditions
Allocation of Rights
Costs The cost of the SORP 2024 is assumed to amount to a total of approximately MSEK 2.5, excluding social security contributions, and is based on the following assumptions: the TSR target has been calculated in accordance with IFRS 2 supported by the Monte Carlo valuation model based on the following assumptions: (i) a closing share price on Nasdaq First North Growth Market on 10 April 2024 corresponding to SEK 34.50, (ii) a volatility of 45 per cent, and (iii) a risk-free interest rate of 2.75 per cent. Based on the same assumptions as above, and subject to social security contributions of 25 per cent, and a share price increase of approximately 40.5 per cent from the start of the SORP 2024 until the participants are allotted Performance Shares (corresponding to a yearly TSR of 12 per cent), the costs of social security contributions are estimated to amount to approximately MSEK 1.6. To illustrate, assuming that 127,844 Performance Shares are allotted at approximately SEK 48.47 per Mentice share, that the actual market price at the time of the free of charge allocation amounts to approximately MSEK 6.2 and with other conditions equal regarding social security contributions, the total cost for the Company of the SORP 2024 would amount to approximately MSEK 4. Effects on key ratios and dilution The SORP 2024 is expected to have only a marginal impact on key performance indicators. Preparation of the proposal Additional ongoing share-based incentive programmes Delivery of Performance Shares in accordance with the SORP 2024 13 B. Directed issue of warrants under the SORP 2024 and approval of subsequent transfer of warrants The issue of warrants shall be subject to the following conditions:
The subscription price, as set out above, shall be rounded to the nearest SEK 0.10, whereby SEK 0.05 shall be rounded downwards. The subscription price and the number of shares that each warrant entitles to subscription for shall be recalculated in the event of a split, consolidation, new share issue etc. in accordance with market practice. The detailed terms of the warrants are set out in Appendix A. It is further proposed that the board of directors, or whomever they appoint, should be authorized to undertake such minor adjustments in the resolution that may be required for the registration with the Swedish Companies Registration Office. Majority requirements and special authorisations The Board of Directors proposes that the Annual General Meeting instructs the Board of Directors to execute the resolution above and to ensure that the SORP 2024 is implemented in accordance with what is stated above. The Board further proposes that the Annual General Meeting instruct the Board, or whomever the Board appoints, to make such minor adjustments in the abovementioned proposed resolutions that may prove necessary in connection with registration with the Swedish Companies Registration Office. Number of shares and votes Majority requirements Meeting documents Questions Processing of personal data __________________________ Gothenburg, April 2024 The board of directors in Mentice AB |
||||||||||||||||||||||||||||||||||||||
2024-04-02 | Mentice | Mentice receives an order of USD 795,000 for development services from a world-leading MedTech company | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-04-02 | Mentice | Mentice får en order på tjänster på mjukvaruutveckling värd USD 795,000 från ett världsledande medtech bolag | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-03-27 | Penser Access by Carnegie | Penser Access by Carnegie: Mentice - Analytikerpresentation | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-03-26 | Penser Access by Carnegie | Penser Access by Carnegie: Mentice - Kapitalmarknadsdag visar vägen framåt | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-03-26 | Mentice | Mentice AB: BioStock: Mentice uppdaterar strategi och mål på kapitalmarknadsdag | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-03-26 | Mentice | Mentice AB: BioStock: Mentice updates strategy and goals at Capital Markets Day | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-03-21 | Mentice | Mentice presenterar finansiella mål och uppdaterad strategisk inriktning för att dra nytta av aktuella marknadsmöjligheter | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-03-21 | Mentice | Mentice presents financial targets and updated strategic direction to take advantage of current market opportunities | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-03-06 | Mentice | Mentice AB: BioStock: Mentice främjar kardiovaskulära innovationer genom samarbete med UNICEN | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-02-23 | Mentice | Invitation to Mentice’s Capital Markets Day on 21 March 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-02-21 | Mentice | Mentice and UNICEN Announce Collaboration to Advance Cardiovascular Healthcare Technologies | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-02-19 | Penser Access by Carnegie | Penser Access by Carnegie: Mentice - Q4 i linje med våra förväntningar | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-02-16 | Mentice | Mentice AB: BioStock: Mentice rapporterar ett starkt fjärde kvartal | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-02-16 | Redeye | Redeye: Mentice Q4 2023 - Ability is nothing without opportunity | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-02-15 | Mentice | Mentice publicerar bolagets bokslutskommuniké för perioden januari–december 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-02-15 | Mentice | Mentice publishes the company’s year-end report for the period January–December 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-02-08 | Mentice | Mentice to present Year-end Report Q4 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-01-05 | Mentice | Mentice AB: BioStock: Mentice får FDA-godkännande för beslutsstödprogram | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-01-04 | Mentice | Mentice receives FDA 510(k) Clearance for ANKYRAS™ | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2024-01-04 | Mentice | Mentice får FDA 510(k)-godkännande för ANKYRAS™ | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-12-22 | Mentice | Mentice receives an order of EUR 1,733,200 for simulation solutions from a world leading MedTech company | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-12-22 | Mentice | Mentice får en order på simuleringslösningar värd EUR 1 733 200 från ett av världsledande medtech bolag | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-12-22 | Mentice | Mentice AB: BioStock: Mentices vd kommenterar förvärvet av franska Biomodex | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-12-15 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Mentice - Carnegie Investment Bank - 15 dec 2023 | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-12-11 | Mentice | Mentice ingår avtal om att förvärva alla huvudsakliga tillgångar från Biomodex, en ledande leverantör av 3D-printade blodkärl och flödessystem | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-12-11 | Mentice | Mentice enters agreement to acquire all substantial assets from Biomodex, a leading provider of 3D-printed vessels and flow systems | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-11-27 | Mentice | Mentice AB: BioStock: Mentices vd: "Vi har marknadens mest avancerade lösningar" | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-11-23 | Mentice | Mentice AB: BioStock: Mentices huvudägare Howell ökar innehavet | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-11-22 | Mentice | Mentice appoints Ulrika Drotz Voksepp as new Chief Financial Officer | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-11-22 | Mentice | Mentice utser Ulrika Drotz Voksepp till ny Chief Financial Officer | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-10-30 | Redeye | Redeye: Mentice Q3 2023 - Delivering profitable growth | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-10-30 | Mentice | Mentice AB: BioStock: Mentices vd om försäljningstillväxten under Q3 | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-10-27 | Penser Access | Penser Access: Visar att en ny nivå av skalbarhet är nådd - Mentice | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-10-27 | Penser Access | Penser Access: Intervju med Mentice - Erik Penser Bank - 26 oktober 2023 | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-10-27 | Mentice | Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-10-27 | Mentice | Valberedningen inför Mentice AB (publ) årsstämma 2024 är utsedd | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-10-26 | Mentice | Mentice publicerar bolagets delårsrapport för perioden juli–sept 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-10-26 | Mentice | Mentice publishes the company’s interim report for the period July – Sept 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-10-19 | Mentice | Mentice's CEO Göran Malmberg to present the company's interim report during a live webcast on October 26 at 10:00 CEST | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-10-04 | Mentice | Mentice får en order på simuleringslösningar värd USD 1,008,000 från ett av världsledande medtech bolag | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-10-04 | Mentice | Mentice receives an order of 1,008,000 USD for simulation solutions from a world-leading MedTech company | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-09-20 | Mentice | Mentice har erhållit en betydande order för simuleringslösningar från en större distributör i APAC | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-09-20 | Mentice | Mentice has received a significant order from a key distributor in APAC | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-09-08 | Mentice | Mentice strengthens leadership team with the appointment of Chief Operating Officer (COO) | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-09-08 | Mentice | Mentice förstärker sin företagsledning genom att utse en Chief Operation Officer (COO) | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-08-15 | Mentice | Mentice announces the latest release of Ankyras in the EU | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-07-21 | Penser Access | Penser Access: Intervju med Mentice - Erik Penser Bank - 20 juli 2023 | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-07-21 | Penser Access | Penser Access: Nått ny nivå av försäljning och lönsamhet - Mentice | Pressreleaser | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-07-21 | Redeye | Redeye: Mentice Q2 2023 - Sales growth and margin expansion | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-07-20 | Mentice | Mentice appoints Henrik Hang as Interim Chief Financial Officer CFO | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-07-20 | Mentice | Mentice utser Henrik Hang till Interim CFO | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-07-20 | Mentice | Mentice publishes the company’s interim report for the period April – June 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-07-20 | Mentice | Mentice publicerar bolagets delårsrapport för perioden april–juni 2023 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-07-07 | Mentice | Correction: Mentice's CEO Göran Malmberg to present the company's interim report at a webcast conference call on July 20 at 10:00 CEST. | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-07-07 | Mentice | Mentice's CEO Göran Malmberg to present the company's interim report at a webcast conference call on July 20 at 10:00 CEST. | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-06-29 | Mentice | Mentice Expands Cooperation in China with Siemens Healthineers | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-05-29 | Mentice | Mentice announces resignation of Chief Financial Officer | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-05-29 | Mentice | Mentice Chief Financial Officer lämnar bolaget | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-05-22 | Mentice | Mentice receives an order of 2.4 million USD for simulation solutions from a top 20 global MedTech company | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-05-22 | Mentice | Mentice får en order på simuleringslösningar värd USD 2,4 miljoner från ett topp 20 globalt medtech bolag | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-05-19 | Mentice | Mentice receives an order of 578,000 USD for simulation solutions from a world leading MedTech company | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-05-19 | Mentice | Mentice får en order på simuleringslösningar värd USD 578,000 från ett av världens ledande medtech bolag | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-05-11 | Mentice | Kommuniké från årsstämma i Mentice AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-05-11 | Mentice | Communique from annual general meeting in Mentice AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
2023-05-09 | Mentice | Mentice Opens Strategic Hub for Software Development | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||||||||||||||||||||||
|